-
Mashup Score: 25A Systematic Review of the Therapeutic Outcome of Mucormycosis - 3 month(s) ago
Untreated mucormycosis has a 100% mortality, reduced to ~32% with amphotericin B, ~14% with amphotericin B followed by azole (possible survivor bias), 17-25% wi
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Outcomes of ATG-PTCY-CSA vs. ATG-based Prophylaxis for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation - 3 month(s) ago
For 10/10 human leukocyte antigen (HLA)-matched unrelated donor (MUD) peripheral blood (PB) allo-HCT, anti-thymocyte globulin (ATG) combined with other immunosuppressive agents is broadly used in Europe for GVHD prevention1. Prospective data have demonstrated that ATG effectively depletes donor and recipient T-cells reducing the risk of graft rejection and GVHD1-6. Nevertheless, using ATG has been associated with non-desirable adverse outcomes such as infectious complications and delayed immune reconstitution7-9.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Danish Cancer Society.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Osteoporosis drug Prolia increases the risk of severe hypocalcemia - 4 month(s) ago
Patients on dialysis or with mineral and bone disorder at highest risk
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML - 4 month(s) ago
Key Points. Maintenance treatment was safe with low rates of infections and chronic GVHD, and minimal impact on T cell-immune reconstitution.With 2-year follow-
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors - 4 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Program: Oral and Poster Abstracts Type: Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management Hematology Disease Topics & Pathways: Research, Lymphoid Leukemias, ALL, Acute Myeloid Malignancies, AML, adult, Clinical Research, GVHD, Diseases, Immune Disorders, real-world evidence, registries, Lymphoid Malignancies, Myeloid Malignancies, Study Population, Human Jeffery J. Auletta, MD 1, Monzr M. Al Malki, MD 2, Todd DeFor, MS 3 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 314Peri‐procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH - 6 month(s) ago
Patients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable. In this document, the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis aims to provide useful practice guidance in the management of antithrombotic agents and thrombocytopenia around the time of common procedures in patients with cancer.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 129Late‐onset Pneumocystis jirovecii pneumonia post‐allogeneic stem cell transplantation after time‐dependent discontinuation of prophylaxis - 6 month(s) ago
Introduction Pneumocystis jirovecii pneumonia (PJP) is a rare complication of hematopoietic stem cell transplantation (HSCT). Primary prophylaxis for 6–12 months post-HSCT is the standard approach. …
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
RT @dwdenning: Outcome from mucormycosis varies by drug therapy & surgery. Just out in OFID: https://t.co/0TXHrW9wyx. AmB alone =31.5% mort…